During his first nine months in office, President Donald Trump announced numerous executive actions aimed at lowering the cost of prescription drugs in the United States. But Americans still pay three times more than their peers for prescription drugs. Why is there a gap between the president’s rhetoric and realized reforms?
Nearly all Americans agree that prescription costs are too high, and it’s no wonder the president is focusing on this issue as a cornerstone of his second term. But while the president has mastered the headlines, he has not mastered the policies. His latest proposals, such as the most-favored-nation movement and drug tariffs, promise to cut costs while quietly raising prices and jeopardizing access to essential medicines.
I wrote in the Worcester Telegram and Gazette last weekend about the gap between Trump’s flashy headlines and a truthful, practical roadmap for prescription drug policy. You can read more here.
